( OTC-BB:AHRO )

News from atheronova inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 03, 2015, 08:45 ET AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection

AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and its subsidiary, AtheroNova Operations, Inc., filed voluntary petitions under...


Feb 19, 2015, 16:48 ET AtheroNova Receives Additional Notices of Debt Acceleration

 AtheroNova Inc. (OTCQB: AHRO) today announced that after its filing of a Current Report on Form 8-K disclosing that on February 12, 2015 it...


Feb 13, 2015, 15:23 ET AtheroNova Receives Notice of Debt Acceleration

 AtheroNova Inc. (OTCQB: AHRO) today announced that it filed a Current Report on Form 8-K disclosing that on February 12, 2015 it received a...


Feb 13, 2015, 08:10 ET AtheroNova Receives Notice of Issuance of Its 3rd US Patent

 AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat...


Oct 31, 2014, 16:13 ET AtheroNova Announces Closing of Public Offering of Common Stock and Warrants

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Oct 28, 2014, 17:58 ET AtheroNova Prices Public Offering of Common Stock and Warrants

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Jul 30, 2014, 07:00 ET AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Dec 05, 2013, 07:00 ET AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Oct 15, 2013, 07:00 ET Atherosclerosis Researcher Dr. Erik Stroes Joins AtheroNova's Clinical Advisory Board

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Sep 19, 2013, 07:00 ET AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Jun 27, 2013, 08:00 ET AtheroNova Announces Publication of Positive Pre-Clinical Results with AHRO-001 in the FASEB Journal

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Jun 25, 2013, 07:00 ET AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...


May 30, 2013, 08:01 ET AtheroNova Announces Shipment of Phase 1 Drug Product

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


May 09, 2013, 07:00 ET AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...


Apr 15, 2013, 13:37 ET Noted Atherosclerosis Researcher Joins AtheroNova Team

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...


Apr 11, 2013, 07:00 ET AtheroNova Adds New Medical Advisor

 AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Mar 14, 2013, 18:18 ET AtheroNova Announces Shareholder Realignment

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Jan 17, 2013, 07:00 ET AtheroNova to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...


Jan 08, 2013, 08:00 ET AtheroNova Names New Clinical Affairs Officer

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Dec 18, 2012, 08:00 ET AtheroNova Names New Chief Medical Officer

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...


Nov 15, 2012, 07:22 ET AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383

AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic...


Nov 13, 2012, 08:00 ET AtheroNova Announces Milestone Filing of IND in Russian Federation

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Nov 07, 2012, 08:22 ET AtheroNova Names New Director

 AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque...


Oct 11, 2012, 09:26 ET AtheroNova Completes $2.9 Million Private Placement of Common Stock

 AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress...


Oct 09, 2012, 08:49 ET Additional Study to Commence at The David Geffen School of Medicine at the University of California Los Angeles (UCLA)

 AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress...